Kailera Therapeutics

Clinical-stage biopharma developing next-generation injectable and oral GLP-1-based therapies for obesity.

View on the globe

$600MEquity raised in 2025–20262025 $600M · 2026 — · 1 equity round
$1BEquity raised, all time2 equity rounds sourced so far
—Latest valuationnot disclosed

Rounds over time log-scaled amounts

Funding history: 2 rounds from Oct 2024 to 14 Oct 2025, $1B equity disclosed. Earlier rounds exist but are not sourced.Oct 2024: Series A, $400M; 14 Oct 2025: Series B, $600M$10M$30M$100M$300M$1BEarlier rounds exist but are not sourced yet← earlier rounds not sourcedQ42025Q2Q3Q42026Equity round14 Oct 2025 · Series B · $600M · led by Bain CapitalOct 2024 · Series A · $400MSeries B · $600MSeries A · $400M
Funding history: 2 rounds from Oct 2024 to 14 Oct 2025, $1B equity disclosed. Earlier rounds exist but are not sourced.Oct 2024: Series A, $400M; 14 Oct 2025: Series B, $600M$10M$30M$100M$300M$1BEarlier rounds exist but are not sourced yetearlier rounds not sourcedQ42025Q2Q3Q42026Equity round14 Oct 2025 · Series B · $600M · led by Bain CapitalOct 2024 · Series A · $400M$600M$400M

Funding history 2 rounds · 2 sources · newest first

Earlier rounds not yet sourced. Kailera Therapeutics was founded in 2024 and raised before Oct 2024; only the rounds below are sourced so far, so its all-time equity total understates its history.

  1. Series B
    Amount$600M
    Post-money—
    ✓ Confirmed
    Lead
    Bain Capital
    Also
    Adage Capital Management, CPP Investments, Royalty Pharma
    Note
    Led by Bain Capital Private Equity. BioPharma Dive also names an investment fund of the Qatari government and unnamed crossover investors; BioSpace adds an undisclosed large mutual fund. Company release (investors.kailera.com) returned 403. The April 2026 Nasdaq IPO (mentioned in a Hengrui release) is not recorded for lack of a sourced amount.
    Sources
  2. Series A
    Amount$400M
    Post-money—
    ◔ Reported
    Note
    Launch financing; BioSpace (2025-10-14) says Kailera launched in October 2024 with a $400M Series A. Investors not named on a page opened.
    Sources
  3. Earlier rounds not yet sourced

Investors 4

  • Bain Capital1
  • Adage Capital Management
  • CPP Investments
  • Royalty Pharma

Highlighted investors led at least one equity round; the number is equity rounds taken part in.

Related companies shared investors

Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. Kailera Therapeutics and its logo are trademarks of their owners, used here for identification only.